Skip to content
‹ Back to IndustriesHealthcare

M&A Healthcare Advisors (MAHA) Exclusively Represents Hoover Pharmacy in their Sale to CVS

LOS ANGELES, March 28, 2023 /PRNewswire/ — M&A Healthcare Advisors (MAHA), a boutique merger and acquisition (M&A) advisory group, is proud to announce the sale of Hoover Pharmacy, a Specialty & Retail Pharmacy based in the San Francisco Bay area focused on serving Stanford Medical Campus patients. Hoover Pharmacy’s files were acquired by CVS and…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share
M&A Healthcare Advisors (MAHA) Exclusively Represents Hoover Pharmacy in their Sale to CVS

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

LOS ANGELES, March 28, 2023 /PRNewswire/ — M&A Healthcare Advisors (MAHA), a boutique merger and acquisition (M&A) advisory group, is proud to announce the sale of Hoover Pharmacy, a Specialty & Retail Pharmacy based in the San Francisco Bay area focused on serving Stanford Medical Campus patients. Hoover Pharmacy’s files were acquired by CVS and all patients will now receive dispensing service at their local Palo Alto branch.

“Andre and his team were instrumental in driving value for our pharmacy and securing the ideal buyer to meet our specific sale criteria. His reliable and consistent guidance allowed us to focus on maintaining operations throughout the transaction while introducing a buyer that would faithfully continue our legacy of care with our patients across the bay area”, Jonathan Han, COO of Hoover Pharmacy.

While there is currently a sense of uncertainty in the larger economy, healthcare M&A remains active with the successful acquisition of Hoover being another great example of the resiliency of lower-middle market healthcare. The team at M&A Healthcare Advisors provided attentive and expert guidance, allowing the Hoover ownership team to achieve their unique sale goals on the identified timeline.

“We are very proud of the level of service we provide to our clients and the successful and efficient sale of Hoover Pharmacy speaks to the client-centric focus we strive for as an organization. Andre’s contributions and representation of the Hoover ownership team was commendable and demonstrates our belief that having an experienced and dedicated sell side advisor greatly increases the probability of achieving a successful outcome”, say Co-Founders Mark Thomas & Mike Moran.

This sale continues the tradition of excellence put in place by M&A Healthcare Advisors.

About M&A Healthcare Advisors

M&A Healthcare Advisors (MAHA), is a boutique merger and acquisition (M&A) advisory group, focused on the lower-middle market healthcare industry. Their core purpose is to provide comprehensive, efficient, and committed transactional support for emerging or established, lower-middle market healthcare businesses.

The team at M&A Healthcare Advisors has sold companies in a variety of healthcare segments: Behavioral Health, Autism Services, I/DD, Hospice, Home Health, Home Care, Private Duty, Physical Therapy, Staffing/Medical Recruiting, Facility-Based Care, Not-for-Profits, and all types of Pharmacy. Their full suite of services includes Sell-Side Representation, M&A Hourly Consulting, and Expert Valuation services.

Business Contact

Mark Thomas

Partner, Director of Operations

M&A Healthcare Advisors

mthomas@mahealthcareadvisors.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

How Memorial Hermann measured $37,500 in AI scribe value per ER doctor

How Memorial Hermann measured $37,500 in AI scribe value per ER doctor

Memorial Hermann emergency physicians using Ambience Healthcare's AI documentation generated about $37,500 more in yearly productivity value than non-users. That figure is gross and comparative. It comes from billing data annualized over 160 shifts and excludes software costs, so buyers must build the cost side themselves.

  • 01Memorial Hermann's $37,500 per emergency physician is gross: the gap in work RVUs per clinical hour between AI documentation users and non-users, annualized over 160 ten-hour shifts, before any software or implementation cost.
  • 02Divided out, that gain comes to roughly $234 a shift or about $23 per clinical hour, a practical yardstick to hold against any all-in per-physician cost quote.
  • 03When a vendor puts fees at risk against outcomes, the comparison group, billing source and acuity adjustment become contract terms, because they decide what counts as a gain worth paying for.

Nov 21, 2026

Capsa's RoboPharma HV Wall is the first central fill system confirmed compatible with Parcel Health's paper vials

Capsa's RoboPharma HV Wall is the first central fill system confirmed compatible with Parcel Health's paper vials

Capsa Healthcare says its RoboPharma HV Wall is the first central fill automation system confirmed to fill Parcel Health’s Tully Tube, a paper prescription vial. The confirmation matters because central fill and mail order sites can only use containers their machines can handle—but this applies to the HV Wall specifically and is not a named production deployment. Buyers can see the vials at ASHP Midyear, Dec. 6–9.

  • 01A central fill site can't switch to a paper vial its automation can't handle. Confirmed machine compatibility is the gate, and the RoboPharma HV Wall is the first system through it for the Tully Tube.
  • 02The up to 71 percent plastic reduction per unit is a ceiling measured against a similar-size plastic vial, so operators modeling sustainability targets should ask for the comparison basis for their own vial sizes.

Nov 20, 2026

Luminopia's CEO says payer churn slows coverage and can require patching first

Luminopia's CEO says payer churn slows coverage and can require patching first

Luminopia co-founder and CEO Scott Xiao told HLTH's Partner Highlight series that short payer member tenure and a fragmented Medicaid leave pediatric amblyopia neglected. A 2025 JMCP payer roundtable recommended covering the FDA-authorized therapy but allowed step-edits, while PEDIG data show two-hour patching adds about 1.1 lines of acuity. Cleveland Clinic registry data report 1.8 lines of gain in severe cases.

  • 01A 2025 payer roundtable in the Journal of Managed Care & Specialty Pharmacy recommended plans cover Luminopia, yet said step-edits and letters of exception may still be required, with more than 9,000 prescriptions written since November 2022.
  • 02PEDIG's ATS05 trial put two hours of daily patching at 1.1 lines of gain over five weeks versus 0.5 lines for glasses alone, while a 2015 AAO review tied patching's poor compliance to social stigma.
  • 03S.1702, the Access to Prescription Digital Therapeutics Act of 2025, has sat in the Senate Finance Committee since May 8, 2025, leaving coverage negotiated plan by plan.

Nov 19, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512